Phenotypic Spectrum of <i>DNM2</i> -Related Centronuclear Myopathy
Leslie Hotchkiss Hayes, Morgane Perdomini, Asli Aykanat, Casie A. Genetti, Heather Paterson, Belinda S. Cowling, Christian Freitag, Alan H. Beggs
Abstract
<h3>Background and Objectives</h3> Centronuclear myopathy (CNM) due to mutations in the dynamin 2 gene, <i>DNM2</i>, is a rare neuromuscular disease about which little is known. The objective of this study was to describe the range of clinical presentations and subsequent natural history of <i>DNM2</i>-related CNM. <h3>Methods</h3> Pediatric and adult patients with suspicion for a CNM diagnosis and confirmed heterozygous pathogenic variants in <i>DNM2</i> were ascertained between December 8, 2000, and May 1, 2019. Data were collected through a retrospective review of genetic testing results, clinical records, and pathology slides combined with patient-reported clinical findings via questionnaires. <h3>Results</h3> Forty-two patients with <i>DNM2</i>-related CNM, whose ages ranged from 0.95 to 75.76 years at most recent contact, were enrolled from 34 families in North or South America and Europe. There were 8 different <i>DNM2</i> pathogenic variants within the cohort. Of the 32 biopsied patients, all had histologic features of CNM. The disease onset was in infancy or childhood in 81% of the cohort, and more than half of the patients had high arched palates, indicative of weakness in utero. Ambulation was affected in nearly all (92%) the patients, and while the rapidity of progression was variable, most (67%) reported a “deteriorating course.” Ptosis, ophthalmoparesis, facial weakness, dysphagia, and respiratory insufficiency were commonly reported. One-third of the patients experienced restricted jaw mobility. Certain pathogenic variants appear to correlate with a more severe phenotype. <h3>Discussion</h3> <i>DNM2</i>-related CNM has a predominantly early-onset, often congenital, myopathy resulting in progressive difficulty with ambulation and occasionally bulbar and respiratory dysfunction. This detailed characterization of the phenotype provides important information to support clinical trial readiness for future disease-modifying therapies.